tag:blogger.com,1999:blog-4908756863334307252.post2587515201151348156..comments2024-01-08T14:02:59.211-08:00Comments on Brain Today: Solanezumab – Another monoclonal antibody reaches Phase IIIDennis Fortierhttp://www.blogger.com/profile/04495517779435972130noreply@blogger.comBlogger2125tag:blogger.com,1999:blog-4908756863334307252.post-82881053800976906592011-05-13T19:33:06.261-07:002011-05-13T19:33:06.261-07:00Actually, by removing the soluble beta-amyloid out...Actually, by removing the soluble beta-amyloid out of the brain, it is thought that beta-amyloid plaques will begin to release oligomers that can be removed as well. The time that it takes for plaque break-down to occur will be much longer than the removal of the soluble form.<br />Michael Rafii, MD, PhDMichael Rafii, MD, PhDhttps://www.blogger.com/profile/08259823552233857796noreply@blogger.comtag:blogger.com,1999:blog-4908756863334307252.post-74472453563553932072011-05-11T21:30:22.194-07:002011-05-11T21:30:22.194-07:00As I understand it, Solanezumab works by drawing S...As I understand it, Solanezumab works by drawing SOLUBLE A-Beta away from the brain, binding the protein with a monoclonal antibody designed to target it. Thus it may not reduce plaques already formed, but may hinder the soluble A-Beta (including 'oligomers' - dimers, trimers, etc. of amyloid-beta) - preventing these free-floating proteins from interfering with synaptic communication/ transmission - is this correct?Lewhttps://www.blogger.com/profile/17546331759318027932noreply@blogger.com